Cholesteryl Ester Transfer Protein and Its Inhibition

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2010 Jun 18

PMID 20556633

Citations 9

Authors

Olaf Weber

Hilmar Bischoff

Carsten Schmeck

Michael-Friedrich Bottcher

Affiliations

Soon will be listed here.

Abstract

Cholesteryl ester transfer protein (CETP) is a plasma glycoprotein that facilitates the transfer of cholesteryl esters from the atheroprotective high density lipoprotein (HDL) to the proatherogenic low density lipoprotein cholesterol (LDL) and very low density lipoprotein cholesterol (VLDL) leading to lower levels of HDL but raising the levels of proatherogenic LDL and VLDL. Inhibition of CETP is considered a potential approach to treat dyslipidemia. However, discussions regarding the role of CETP-mediated lipid transfer in the development of atherosclerosis and CETP inhibition as a potential strategy for prevention of atherosclerosis have been controversial. Although many animal studies support the hypothesis that inhibition of CETP activity may be beneficial, negative phase III studies on clinical endpoints with the CETP inhibitor torcetrapib challenged the future perspectives of CETP inhibitors as potential therapeutic agents. The review provides an update on current understanding of the molecular mechanisms involved in CETP activity and its inhibition.

Citing Articles

Voluntary exercise fails to prevent metabolic dysfunction-associated steatotic liver disease progression in male rats fed a high-fat high-cholesterol diet.

Besqueut-Rougerie C, Chavanelle V, Michaux A, Otero Y, Sirvent P, King J Physiol Rep. 2024; 12(8):e15993.

PMID: 38627215 PMC: 11021195. DOI: 10.14814/phy2.15993.

New Diterpenes from Cultures of the Fungus Engleromyces goetzii and Their CETP Inhibitory Activity.

Wang Y, Zhang L, Wang F, Li Z, Dong Z, Liu J Nat Prod Bioprospect. 2015; .

PMID: 25850378 PMC: 4402584. DOI: 10.1007/s13659-015-0055-5.

Addressing phenoconversion: the Achilles' heel of personalized medicine.

Shah R, Smith R Br J Clin Pharmacol. 2014; 79(2):222-40.

PMID: 24913012 PMC: 4309629. DOI: 10.1111/bcp.12441.

Cholesteryl ester transfer protein (CETP) -629C/A polymorphism and it's effects on the serum lipid levels in metabolic syndrome patients.

Akbarzadeh M, Hassanzadeh T, Saidijam M, Esmaeili R, Borzouei S, Hajilooi M Mol Biol Rep. 2012; 39(10):9529-34.

PMID: 22729881 DOI: 10.1007/s11033-012-1817-3.

Genistein as a potential inducer of the anti-atherogenic enzyme paraoxonase-1: studies in cultured hepatocytes in vitro and in rat liver in vivo.

Schrader C, Ernst I, Sinnecker H, Soukup S, Kulling S, Rimbach G J Cell Mol Med. 2012; 16(10):2331-41.

PMID: 22304296 PMC: 3823426. DOI: 10.1111/j.1582-4934.2012.01542.x.

References

Sugano M, Makino N, Sawada S, Otsuka S, Watanabe M, Okamoto H . Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem. 1998; 273(9):5033-6. DOI: 10.1074/jbc.273.9.5033. View

Parini P, Rudel L . Is there a need for cholesteryl ester transfer protein inhibition?. Arterioscler Thromb Vasc Biol. 2003; 23(3):374-5. DOI: 10.1161/01.ATV.0000060447.25136.1C. View

Rennings A, Stalenhoef A . JTT-705: is there still future for a CETP inhibitor after torcetrapib?. Expert Opin Investig Drugs. 2008; 17(10):1589-97. DOI: 10.1517/13543784.17.10.1589. View

Thompson A, Di Angelantonio E, Sarwar N, Erqou S, Saleheen D, Dullaart R . Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA. 2008; 299(23):2777-88. DOI: 10.1001/jama.299.23.2777. View

Hunt J, Lu Z . Cholesteryl ester transfer protein (CETP) inhibitors. Curr Top Med Chem. 2009; 9(5):419-27. DOI: 10.2174/156802609788340823. View

Maeda K, Okamoto H, Shinkai H . S-(2-(acylamino)phenyl) 2,2-dimethylpropanethioates as CETP inhibitors. Bioorg Med Chem Lett. 2004; 14(10):2589-91. DOI: 10.1016/j.bmcl.2004.02.071. View

Yusuf S, Reddy S, Ounpuu S, Anand S . Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001; 104(22):2746-53. DOI: 10.1161/hc4601.099487. View

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

Cunningham D, Lin W, Hoth L, Danley D, Ruggeri R, Geoghegan K . Biophysical and biochemical approach to locating an inhibitor binding site on cholesteryl ester transfer protein. Bioconjug Chem. 2008; 19(8):1604-13. DOI: 10.1021/bc800165n. View

10.

Yancey P, Bortnick A, Kellner-Weibel G, de la Llera-Moya M, Phillips M, Rothblat G . Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol. 2003; 23(5):712-9. DOI: 10.1161/01.ATV.0000057572.97137.DD. View

11.

Nagano M, Yamashita S, Hirano K, Takano M, Maruyama T, Ishihara M . Molecular mechanisms of cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler Thromb. 2004; 11(3):110-21. DOI: 10.5551/jat.11.110. View

12.

Lebherz C, Sanmiguel J, Wilson J, Rader D . Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent. Cardiovasc Diabetol. 2007; 6:15. PMC: 1868709. DOI: 10.1186/1475-2840-6-15. View

13.

Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H . A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature. 2000; 406(6792):203-7. DOI: 10.1038/35018119. View

14.

Chajek T, Fielding C . Isolation and characterization of a human serum cholesteryl ester transfer protein. Proc Natl Acad Sci U S A. 1978; 75(7):3445-9. PMC: 392794. DOI: 10.1073/pnas.75.7.3445. View

15.

Moreno P, Sanz J, Fuster V . Promoting mechanisms of vascular health: circulating progenitor cells, angiogenesis, and reverse cholesterol transport. J Am Coll Cardiol. 2009; 53(25):2315-23. DOI: 10.1016/j.jacc.2009.02.057. View

16.

Barzilai N, Atzmon G, Schechter C, Schaefer E, Cupples A, Lipton R . Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA. 2003; 290(15):2030-40. DOI: 10.1001/jama.290.15.2030. View

17.

Neeli H, Rader D . Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?. Cardiol Clin. 2008; 26(4):537-46. DOI: 10.1016/j.ccl.2008.06.005. View

18.

Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2):227-39. DOI: 10.1161/01.CIR.0000133317.49796.0E. View

19.

Nissen S, Tardif J, Nicholls S, Revkin J, Shear C, Duggan W . Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007; 356(13):1304-16. DOI: 10.1056/NEJMoa070635. View

20.

Rano T, Sieber-McMaster E, Pelton P, Yang M, Demarest K, Kuo G . Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform. Bioorg Med Chem Lett. 2009; 19(9):2456-60. DOI: 10.1016/j.bmcl.2009.03.051. View